Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): Experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis

Burns

Volumn 33, Issue 4, 2007, Pages 452-459

  Stella, Maurizio ^a   Clemente, Alessandra ^a   Bollero, Daniele ^a   Risso, Daniela ^a   Dalmasso, Paola ^b  

^a CTO HOSPITAL   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Burn unit; Immunoglobulins; Lyell syndrome; Stevens Johnson syndrome; Toxic epidermal necrolysis

Indexed keywords

BETAMETHASONE; HYDROCORTISONE; IMMUNOGLOBULIN; MEPREDNISONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; MALE; MORTALITY; MUCOSAL DISEASE; RISK FACTOR; SKIN DISEASE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ADULT; AGED; BURNS; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; FLUID THERAPY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STEVENS-JOHNSON SYNDROME; SURVIVAL ANALYSIS;

EID: 34247858950     PISSN: 03054179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.burns.2006.08.014     Document Type: Article

References (46)

1. Yarbrough D.R. Experience with toxic epidermal necrolysis treated in a burn center. J Burn Care Rehabil 17 1 (1996) 30-33
2. Roujeau J.C., Guillaume J.C., and Fabre J.P. Toxic epidermal necrolysis (Lyell syndrome). Arch Dermatol 126 (1990) 37-42
3. Paul C., Wolkenstein P., Adle H., et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 134 4 (1996) 710-714
4. Inachi S., Mizutani H., and Shimizu M. Epidermal apoptotic cell death in erythema multiforme and Stevens-Johnson syndrome. Contribution of perforin-positive cell infiltration. Arch Dermatol 133 7 (1997) 845-849
5. Wehrli P., Viard I., Bullani R., et al. Death receptors in Cutaneous biology and disease. J Invest Dermatol 115 2 (2000) 141-148
6. Viard I., Wehrli P., Bullani R., et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282 (1998) 490-493
7. Roujeau J.C., Kelly J.P., Nalam L., et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 333 21 (1995) 1600-1607
8. Schwartz R.A. Toxic epidermal necrolysis. Cutis 59 3 (1997) 123-128
9. Mofid M.Z., Costarangos C., Bernstein B., et al. Drug-induced linear immunoglobulin A bollous disease that clinically mimics toxic epidermal necrolysis. J Burn Care Rehabil 21 3 (2000) 246-247
10. Cohen A.D., Cagnano E., and Halevy S. Acute generalized exanthematous pustolosis mimicking toxic epidermal necrolysis. Int J Dermatol 40 (2001) 458-461
11. Stella M., Cassano P., Bollero D., Clemente A., and Giorio G. Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience. Dermatology 203 (2001) 45-49
12. Bastuji-Garin S., Zahedi M., Guillaume J.C., and Roujeau J.C. Toxic epidermal necrolysis (Lyell syndrome) in 77 elderly patients. Age Ageing 22 6 (1993) 450-456
13. Schulz J.T., Sheridan R.L., Ryan C.M., et al. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil 21 3 (2000) 199-204
14. Palmieri T.L., Greenhalgh D.G., Saffle J.R., et al. A multicenter review of Toxic Epidermal Necrolysis treated in U.S. Burn Centers at the end of the 20th century. J Burn Care Rehabil 23 2 (2002) 87-96
15. Roujeau J.C. Treatment of severe drug eruptions. J Dermatol 26 11 (1999) 718-722
16. Garcia-Doval I., LeCleach L., Bocquet H., et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?. Arch Dermatol 136 3 (2000) 323-327
17. Wolkenstein P., and Revuz J. Toxic epidermal necrolysis. Dermatol Clin 18 3 (2000) 485-495
18. Kucan J.O. Use of Biobrane in the treatment of toxic epidermal necrolysis. J Burn Care Rehabil 16 3 (1995) 324-327
19. Arevalo J.M., Lorente J.A., Gonzales-Herrada C., and Jimenez-Reyes J. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 48 3 (2000) 473-478
20. Pianigiani E., Ierardi F., Taddeucci P., et al. Skin allograft in the treatment of toxic epidermal necrolysis. Dermatol Surg 28 12 (2002) 1173-1176
21. Criton S., Devi K., and Srivedi P.K. Toxic epidermal necrolysis-a retrospective study. Int J Dermatol 36 12 (1997) 923-925
22. Pasricha J.S., Khaitan B.K., Shantharaman R., et al. Toxic epidermal necrolysis. Int J Dermatol 35 7 (1996) 523-527
23. Revuz J.E., and Roujeau J.C. Advance in toxic epidermal necrolysis. Semin Cutan Med Surg 15 4 (1996) 258-266
24. Cheriyan S., Patterson R., Greenberger P.A., et al. The outcome of Stevens-Johnson syndrome treated with corticosteroids. Allergy Proc 16 4 (1995) 151-155
25. Jarrett P., Rademaker M., Havill J., and Pullon H. Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony stimulating factor. Clin Exp Dermatol 22 3 (1997) 146-147
26. Goulden V., and Goodfield M.J. Recombinant granulocyte colony-stimulating factor in the management of toxic epidermal necrolysis. Br J Dermatol 135 2 (1996) 305-306
27. Frangogiannis N.G., Boridy I., Mazhar M., et al. Cyclophosphamide in the treatment of toxic epidermal necrolysis. South Med J 89 10 (1996) 1001-1003
28. Sullivan J.R., and Watson A. Lamotrigine-induced toxic epidermal necrolysis treat with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management. Aust J Dermatol 37 4 (1996) 208-212
29. Chaidemenos G.C., Chrysomallis F., Sombolos K., et al. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol 36 3 (1997) 218-221
30. Egan C.A., Grant W.J., Morris S.E., et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 40 3 (1999) 458-461
31. Velez A., and Moreno J.C. Toxic epidermal necrolysis treated with N-acetylcisteine. J Am Acad Dermatol 46 3 (2002) 469-470
32. Fischer M., Fiedler E., Marsch W.C., and Wohlrab J. Antitumour necrosis factor-α antibodies (infliximab) in the treatment of a patients with toxic epidermal necrolysis. Br J Dermatol 146 (2002) 705-718
33. Inamo Y., Okubo T., Wada M., et al. Intravenous ulinastatin therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis in pediatric patients. Three case reports. Int Arch Allergy Immunol 127 1 (2002) 89-94
34. Paquet P., Jacob E., Damas P., and Pierard G.E. Treatment of drug-induced toxic epidermal necrolysis (Lyell syndrome) with intravenous human immunoglobulins. Burns 27 6 (2001) 652-655
35. Phan T.G., Wong R.C., Crotty K., and Aldestein S. Toxic epidermal necrolysis in acquired immunodeficiency syndrome treated with intravenous gammaglobulin. Aust J Dermatol 40 3 (1999) 153-157
36. Magina S., Lisboa C., Goncalves E., et al. A case of toxic epidermal necrolysis treated with intravenous immunoglobulin. Br J Dermatol 142 1 (2000) 191-192
37. Tristani-Firouzi P., Peterson M.J., and Saffle J.R. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 47 4 (2002) 548-552
38. Wolff K., and Tappeiner G. Treatment of toxic epidermal necrolysis: the uncertanty persist but the fog is disperding. Arch Dermatol 139 1 (2003 Jan) 85-86
39. Bastuji Garin S., Fouchard N., Bertocchi M., et al. SCORTEN: a severità of illness score for toxic epidermal necrolysis. J Invest Dermatol 115 (2000) 149-153
40. Trent J.T., Kirsner R.S., Romanelli P., et al. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami experience. Arch Dermatol 139 1 (2003) 39-43
41. Bachot N., Revuz J., and Roujeau J.C. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 139 1 (2003) 33-36
42. Curreri P.W., Richmond D., Marvin J., et al. Dietary requirements of patients with major burns. Am Diet Assoc 65 (1974) 415-417
43. Jensen A.G., Wachmann C.H., Poulsen K.B., et al. Risk factors for hospital-acquired Staphylococcus aureus bacteremia. Arch Intern Med 159 13 (1999) 1437-1444
44. Roujeau J.C., Albengres E., Moritz S., et al. Lymphocyte transformation test in toxic epidermal necrolysis (Lyell syndrome). Int Arch Allergy Appl Immunol 78 (1985) 22-24
45. Brown K.M., Silver G.M., Halerz M., Walaszek P., et al. Toxic epidermal necrolysis: does immunoglobulin make a difference?. J Burn Care Rehabil 25 1 (2004) 81-88
46. Prins C., Kardel F.A., Padilla R.S., Hunziker T., et al. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins. Multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 139 (2003) 26-32